カテゴリー： 世界, 医療/バイオ, visiongain

世界の再生医療市場（2023-2033)：製品別（細胞治療（自己由来、同種由来）、組織エンジニアリング（足場材、ヒドロゲル）、遺伝子治療、その他）、用途別（腫瘍、皮膚科、筋骨格、神経内科、循環器科、創傷治療、眼科、その他）、地域別

【英語タイトル】Regenerative Medicine Market Report 2023-2033 : Forecasts by Product (Cell Therapy (Autologous, Allogenic), Tissue Engineering (Scaffold, Hydrogels), Gene Therapy, Others), by Application (Oncology, Dermatology, Musculoskeletal, Neurology, Cardiovascular, Wound Healing, Ophthalmology, Others) AND Regional and Leading National Market Analysis PLUS Analysis of Leading Companies AND COVID-19 Impact and Recovery Pattern Analysis

visiongainが出版した調査資料（VGA23MA027）・商品コード：VGA23MA027
・発行会社（調査会社）：visiongain
・発行日：2023年3月10日
・ページ数：232
・レポート言語：英語
・レポート形式：PDF
・納品方法：Eメール（受注後24時間以内）
・調査対象地域：グローバル
・産業分野：医療
◆販売価格オプション（消費税別）
Sigle User（1名様閲覧用、1年間、印刷不可）GBP3,950 ⇒換算￥750,500見積依頼/購入/質問フォーム
Enterprise（法人閲覧用、1年間、印刷可）GBP6,950 ⇒換算￥1,320,500見積依頼/購入/質問フォーム
※販売価格オプションの説明
※お支払金額：換算金額（日本円）＋消費税
※納期：即日〜2営業日（3日以上かかる場合は別途表記又はご連絡）
※お支払方法：納品日＋5日以内に請求書を発行・送付（請求書発行日より2ヶ月以内に銀行振込、振込先：三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能）
❖ レポートの概要 ❖

Visiongain社の本調査レポートでは、世界の再生医療市場規模が、2033年まで年平均成長率18.40%で拡大すると予想しています。本レポートは、再生医療の世界市場を調査対象とし、レポート概要、エグゼクティブサマリー、市場動向、製品別（幹細胞治療、組織エンジニアリング、遺伝子治療、その他）分析、用途別（腫瘍、皮膚科、筋骨格、神経内科、その他）分析、地域別（北米、ヨーロッパ、アジア太平洋、中南米、中東・アフリカ、アメリカ、カナダ、ドイツ、フランス、イギリス、イタリア、スペイン、ロシア、日本、中国、インド、オーストラリア、韓国、ブラジル、メキシコ、アルゼンチン、中東、南アフリカ、その他地域）分析、企業情報などの項目を掲載しています。また、本レポートには、Amgen、Anterogen、Avita Medical Inc.、Bio Solutions. Co. Ltd、Bluebird Bio Inc.、Bristol Myers Squibb、Gilead Sciences, Inc.、Integra Life Sciences、Misoblast Ltd、Novartis AGなどの企業情報が含まれています。
・レポート概要
・エグゼクティブサマリー
・市場動向
・世界の再生医療市場規模：製品別
- 幹細胞治療の市場規模
- 組織エンジニアリングの市場規模
- 遺伝子治療の市場規模
- その他製品の市場規模
・世界の再生医療市場規模：用途別
- 腫瘍における市場規模
- 皮膚科における市場規模
- 筋骨格における市場規模
- 神経内科における市場規模
- その他用途における市場規模
・世界の再生医療市場規模：地域別
- 北米の再生医療市場規模
アメリカの再生医療市場規模
カナダの再生医療市場規模
- ヨーロッパの再生医療市場規模
ドイツの再生医療市場規模
フランスの再生医療市場規模
イギリスの再生医療市場規模
イタリアの再生医療市場規模
ロシアの再生医療市場規模
- アジア太平洋の再生医療市場規模
日本の再生医療市場規模
中国の再生医療市場規模
インドの再生医療市場規模
オーストラリアの再生医療市場規模
韓国の再生医療市場規模
- 中南米の再生医療市場規模
ブラジルの再生医療市場規模
メキシコの再生医療市場規模
アルゼンチンの再生医療市場規模
- 中東・アフリカの再生医療市場規模
中東の再生医療市場規模
南アフリカの再生医療市場規模
- その他地域の再生医療市場規模
・企業情報

The Regenerative Medicine Market Report 2023-2033: This report will prove invaluable to leading firms striving for new revenue pockets if they wish to better understand the industry and its underlying dynamics. It will be useful for companies that would like to expand into different industries or to expand their existing operations in a new region.

Growing number of Joint Ventures to fuel market growth
The demand for breakthrough techniques in tissue engineering, cell therapy, and stem cell use is increasing due to the rising prevalence of chronic diseases and clinical trials. Continuous joint ventures, mergers, acquisitions, and other strategic activity by various companies is helping the regenerative medicine market thrive. For instance, in October 2022, Dr. Vanessa Rodriguez Pares and Meso Numismatics, Inc. (MSSV), a biotech and numismatics-focused technology company, partnered with the new STEM LIFE clinic facility. This collaboration aims to promote regenerative medicine’s high standards. Similar to this, Astellas Pharma Inc. and Pantherna Therapeutics GmbH entered into a technology evaluation agreement in October 2022 to carry out research to create mRNA-based regenerative medicine programmes employing direct reprogramming (trans-differentiation). Additionally, in October 2020, the world’s largest pharmaceutical corporation Bayer bought Asklepios BioPharmaceutical, a gene therapy business with operations in San Sebastián, Spain, Edinburgh, and Paris, in a deal valued at up to US$ 4 billion. Such actions significantly influence the market for regenerative medicine’s growth pace.

Product Recalls may hamper the market growth
Regenerative medicine is a speedily evolving field and involves the use of wide array of techniques to repair or replace damaged tissues and organs. With the increasing popularity and use of these products, there have been instances of product recalls in the regenerative medicine market. The growth of the regenerative medicine market can be impeded owing to the increasing number of product recalls. Biotech companies continue to face difficulties such as risk of product recalls and marketing their genetic medicine in the market. For instance, Bluebird Bio, a US-based gene therapy company, withdrew its gene therapy for a rare blood disorder from the German market in April 2021 after failing to reach an agreement on the treatment’s cost with German health authorities. This recall impacted the company’s sales and brand image. Similarly, small-scale companies are severely affected as they fail to recover from losses due to product recalls because they operate without robust cash flow and brand recognition.

What Questions Should You Ask before Buying a Market Research Report?
• How is the Regenerative Medicine Market evolving?
• What is driving and restraining the Regenerative Medicine Market?
• How will each Regenerative Medicine submarket grow over the forecast period and how much revenue will these submarkets account for in 2033?
• How will the market shares for each Regenerative Medicine submarket develop from 2023 to 2033?
• What will be the main driver for the overall market from 2023 to 2033?
• Will leading Regenerative Medicine Markets broadly follow the macroeconomic dynamics, or will individual national markets outperform others?
• How will the market shares of the national markets change by 2033 and which geographical region will lead the market in 2033?
• Who are the leading players and what are their prospects over the forecast period?
• What are the Regenerative Medicine development projects for these leading companies?
• How will the industry evolve during the period between 2023 and 2033? What are the implications of Regenerative Medicine development projects taking place now and over the next 10 years?
• Is there a greater need for product commercialisation to further scale the Regenerative Medicine Market?
• Where is the Regenerative Medicine Market heading and how can you ensure you are at the forefront of the market?
• What are the best investment options for new product and service lines?
• What are the key prospects for moving companies into a new growth path and C-suite?

You need to discover how this will impact the Regenerative Medicine Market today, and over the next 10 years:
• Our 232-page report provides 101 tables and 108 charts/graphs exclusively to you.
• The report highlights key lucrative areas in the industry so you can target them – NOW.
• It contains in-depth analysis of global, regional and national sales and growth.
• It highlights for you the key successful trends, changes and revenue projections made by your competitors.

This report tells you TODAY how the Regenerative Medicine Market will develop in the next 10 years, and in line with the variations in COVID-19 economic recession and bounce. This market is more critical now than at any point over the last 10 years.

Forecasts to 2033 and other analyses reveal commercial prospects
• In addition to revenue forecasting to 2033, our new study provides you with recent results, growth rates, and market shares.
• You will find original analyses, with business outlooks and developments.
• Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges), cost structure, impact of rising prices of regenerative medicines and recent developments.

This report includes data analysis and invaluable insight into how COVID-19 will affect the industry and your company. Four COVID-19 recovery patterns and their impact, namely, “V”, “L”, “W” and “U” are discussed in this report.

Segments Covered in the Report

By Product
• Stem Cell Therapy
– Autologous
– Allogenic
• Tissue Engineering
– Scaffold
– Hydrogels
• Gene Therapy
• Others

By Application
• Regenerative Medicine
– Oncology
– Dermatology
– Musculoskeletal
– Neurology
– Cardiovascular
– Wound Healing
– Ophthalmology
– Others

In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for five regional and 16 leading national markets:

North America
• U.S.
• Canada

Europe
• Germany
• UK
• France
• Spain
• Italy
• Rest of Europe

Asia Pacific
• China
• Japan
• India
• Australia
• South Korea
• Rest of Asia Pacific

Latin America
• Brazil
• Mexico
• Rest of Latin America Latin America

MEA
• GCC
• South Africa
• Rest of MEA

The report also includes profiles and for some of the leading companies in the Regenerative Medicine Market, 2023 to 2033, with a focus on this segment of these companies’ operations.

Leading companies and the potential for market growth
• Amgen
• Anterogen
• Avita Medical Inc.
• Bio Solutions. Co. Ltd
• Bluebird Bio Inc.
• Bristol Myers Squibb
• Gilead Sciences, Inc.
• Integra Life Sciences
• Misoblast Ltd
• Novartis AG
• Organogenesis Inc.
• Sarepta Therapeutics,Inc
• Sibino GeneTech Co. Ltd
• Smith & Nephew plc
• Terumo BCT

Overall world revenue for Regenerative Medicine Market, 2023 to 2033 in terms of value the market will surpass US$ 59.15 billion in 2023, our work calculates. We predict strong revenue growth through to 2033. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.

How will the Regenerative Medicine Market, 2023 to 2033 report help you?
In summary, our 232-page report provides you with the following knowledge:

• Revenue forecasts to 2033 for Regenerative Medicine Market, 2023 to 2033 Market, with forecasts for Type of Product and Application at a global and regional level – discover the industry’s prospects, finding the most lucrative places for investments and revenues.

• Revenue forecasts to 2033 for five regional and 16 key national markets – See forecasts for the Regenerative Medicine Market, 2023 to 2033 market in North America, Europe, Asia-Pacific and Latin America and Middle East and Africa. Also forecasted is the market in the US, Canada, Mexico, Brazil, Germany, France, UK, Italy, China, India, Japan, and Australia among other prominent economies.

• Prospects for established firms and those seeking to enter the market – including company profiles of the major companies involved in the Regenerative Medicine Market, 2023 to 2033.

Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with invaluable business intelligence.

Information found nowhere else
With our new report, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your research, analyses, and decisions. Our study is for everybody needing commercial analyses for the Regenerative Medicine Market, 2023 to 2033, market-leading companies. You will find data, trends and predictions.

グローバル市場調査レポート販売サイトのwww.marketreport.jpです。

❖ レポートの目次 ❖

1 Report Overview
1.1 Objectives of the Study
1.2 Introduction to Regenerative Medicine Market
1.3 What This Report Delivers
1.4 Why You Should Read This Report
1.5 Key Questions Answered by This Analytical Report
1.6 Who is This Report for?
1.7 Methodology
1.7.1 Market Definitions
1.7.2 Market Evaluation & Forecasting Methodology
1.7.3 Data Validation
1.7.3.1 Primary Research
1.7.3.2 Secondary Research
1.8 Frequently Asked Questions (FAQs)
1.9 Associated Reports
1.10 About

2 Executive Summary

3 Market Overview
3.1 Key Findings
3.2 Market Dynamics
3.2.1 Market Driving Factors
3.2.1.1 Increasing Strategic Activities and Collaborations
3.2.1.2 Rise in Research and Development Projects
3.2.1.3 Surging Government Support
3.2.2 Market Restraining Factors
3.2.2.1 Substantial Number of Product Recalls
3.2.2.2 Unapproved Products in the Market
3.2.3 Market Opportunities
3.2.3.1 Growing Research Partnership in Developed and Developing Countries across the globe
3.2.3.2 Growing awareness about the advances in medical research
3.2.3.3 Growing Investment and Funding
3.2.4 .COVID-19 Impact Analysis
3.3 Porter’s Five Forces Analysis
3.3.1 Bargaining Power of Suppliers
3.3.2 Bargaining Power of Buyers
3.3.3 Competitive Rivalry
3.3.4 Threat from Substitutes
3.3.5 Threat of New Entrants
3.4 PEST Analysis

4 Regenerative Medicine Market Analysis by Product
4.1 Key Findings
4.2 Product Segment: Market Attractiveness Index
4.3 Regenerative Medicine Market Size Estimation and Forecast by Product
4.4 Stem Cell Therapy
4.4.1 Regenerative Medicine Market Forecast by Stem Cell Therapy, 2023-2033 (US$ Bn)
4.4.1.1 Market Size by Region, 2023-2033 (US$ Bn)
4.4.1.2 Market Share by Region, 2023 & 2033 (%)
4.5 Tissue Engineering
4.5.1.1 Regenerative Medicine Market Forecast by Tissue Engineering, 2023-2033 (US$ Bn)
4.5.1.2 Market Size by Region, 2023-2033 (US$ Bn)
4.5.1.3 Market Share by Region, 2023 & 2033 (%)
4.6 Gene Therapy
4.6.1.1 Market Size by Region, 2023-2033 (US$ Bn)
4.6.1.2 Market Share by Region, 2023 & 2033 (%)
4.7 Others
4.7.1.1 Market Size by Region, 2023-2033 (US$ Bn)
4.7.1.2 Market Share by Region, 2023 & 2033 (%)

5 Regenerative Medicine Market Analysis by Application
5.1 Key Findings
5.2 Product Segment: Market Attractiveness Index
5.3 Regenerative Medicine Market Size Estimation and Forecast by Application
5.4 Oncology
5.4.1 Market Size by Region, 2023-2033 (US$ Bn)
5.4.2 Market Share by Region, 2023 & 2033 (%)
5.5 Dermatology
5.5.1 Market Size by Region, 2023-2033 (US$ Bn)
5.5.2 Market Share by Region, 2023 & 2033 (%)
5.6 Musculoskeletal
5.6.1 Market Size by Region, 2023-2033 (US$ Bn)
5.6.2 Market Share by Region, 2023 & 2033 (%)
5.7 Neurology
5.7.1 Market Size by Region, 2023-2033 (US$ Bn)
5.7.2 Market Share by Region, 2023 & 2033 (%)
5.8 Cardiovascular
5.8.1 Market Size by Region, 2023-2033 (US$ Bn)
5.8.2 Market Share by Region, 2023 & 2033 (%)
5.9 Wound Healing
5.9.1 Market Size by Region, 2023-2033 (US$ Bn)
5.9.2 Market Share by Region, 2023 & 2033 (%)
5.10 Ophthalmology
5.10.1 Market Size by Region, 2023-2033 (US$ Bn)
5.10.2 Market Share by Region, 2023 & 2033 (%)
5.11 Others
5.11.1 Market Size by Region, 2023-2033 (US$ Bn)
5.11.2 Market Share by Region, 2023 & 2033 (%)

6 Regenerative Medicine Market Analysis by Region
6.1 Key Findings
6.2 Regional Segment: Market Attractiveness Index
6.3 Regenerative Medicine Market Size Estimation and Forecast

7 North America Regenerative Medicine Market Analysis
7.1 Key Findings
7.2 North America Regenerative Medicine Market Attractiveness Index
7.3 North America Regenerative Medicine Market by Country, 2023, 2028 & 2033 (US$ Bn)
7.4 North America Regenerative Medicine Market Size Estimation and Forecast by Country
7.5 North America Regenerative Medicine Market Size Estimation and Forecast by Product
7.6 North America Regenerative Medicine Market Size Estimation and Forecast by Application
7.7 U.S. Regenerative Medicine Market Analysis
7.8 Canada Regenerative Medicine Market Analysis

8 Europe Regenerative Medicine Market Analysis
8.1 Key Findings
8.2 Europe Regenerative Medicine Market Attractiveness Index
8.3 Europe Regenerative Medicine Market by Country, 2023, 2028 & 2033 (US$ Bn)
8.4 Europe Regenerative Medicine Market Size Estimation and Forecast by Country
8.5 Europe Regenerative Medicine Market Size Estimation and Forecast by Product
8.6 Europe Regenerative Medicine Market Size Estimation and Forecast by Application
8.7 Germany Regenerative Medicine Market Analysis
8.8 France Regenerative Medicine Market Analysis
8.9 UK Regenerative Medicine Market Analysis
8.10 Italy Regenerative Medicine Market Analysis
8.11 Spain Regenerative Medicine Market Analysis
8.12 Russia Regenerative Medicine Market Analysis
8.13 Rest of Europe Regenerative Medicine Market Analysis

9 Asia Pacific Regenerative Medicine Market Analysis
9.1 Key Findings
9.2 Asia Pacific Regenerative Medicine Market Attractiveness Index
9.3 Asia Pacific Regenerative Medicine Market by Country, 2023, 2028 & 2033 (US$ Bn)
9.4 Asia Pacific Regenerative Medicine Market Size Estimation and Forecast by Country
9.5 Asia Pacific Regenerative Medicine Market Size Estimation and Forecast by Product
9.6 Asia Pacific Regenerative Medicine Market Size Estimation and Forecast by Application
9.7 Japan Regenerative Medicine Market Analysis
9.8 China Regenerative Medicine Market Analysis
9.9 India Regenerative Medicine Market Analysis
9.10 Australia Regenerative Medicine Market Analysis
9.11 South Korea Regenerative Medicine Market Analysis
9.12 Rest of Asia Pacific Regenerative Medicine Market Analysis

10 Latin America Regenerative Medicine Market Analysis
10.1 Key Findings
10.2 Latin America Regenerative Medicine Market Attractiveness Index
10.3 Latin America Regenerative Medicine Market by Country, 2023, 2028 & 2033 (US$ Bn)
10.4 Latin America Regenerative Medicine Market Size Estimation and Forecast by Country
10.5 Latin America Regenerative Medicine Market Size Estimation and Forecast by Product
10.6 Latin America Regenerative Medicine Market Size Estimation and Forecast by Application
10.7 Brazil Regenerative Medicine Market Analysis
10.8 Mexico Regenerative Medicine Market Analysis
10.9 Rest of Latin America Regenerative Medicine Market Analysis

11 MEA Regenerative Medicine Market Analysis
11.1 Key Findings
11.2 MEA Regenerative Medicine Market Attractiveness Index
11.3 MEA Regenerative Medicine Market by Country, 2023, 2028 & 2033 (US$ Bn)
11.4 MEA Regenerative Medicine Market Size Estimation and Forecast by Country
11.5 MEA Regenerative Medicine Market Size Estimation and Forecast by Product
11.6 MEA Regenerative Medicine Market Size Estimation and Forecast by Application
11.7 GCC Regenerative Medicine Market Analysis
11.8 South Africa Regenerative Medicine Market Analysis
11.9 Rest of MEA Regenerative Medicine Market Analysis

12 Company Profiles
12.1 Company share analysis, 2021
12.2 Amgen
12.2.1 Company Snapshot
12.2.2 Company Overview
12.2.3 Financial Analysis
12.2.3.1 Net Revenue, 2017-2021
12.2.3.2 R&D, 2017-2021
12.2.3.3 Regional Market Shares, 2021
12.2.4 Product Benchmarking
12.2.5 Strategic Outlook
12.3 Anterogen
12.3.1 Company Snapshot
12.3.2 Company Overview
12.3.3 Financial Analysis
12.3.3.1 Net Revenue, 2017-2021
12.3.3.2 R&D, 2017-2021
12.3.4 Product Benchmarking
12.4 Avita Medical, Inc.
12.4.1 Company Snapshot
12.4.2 Company Overview
12.4.3 Financial Analysis
12.4.3.1 Net Revenue, 2017-2021
12.4.3.2 R&D, 2017-2021
12.4.3.3 Regional Market Shares, 2021
12.4.4 Product Benchmarking
12.4.5 Strategic Outlook
12.5 Bio Solution Co. Ltd.
12.5.1 Company Snapshot
12.5.2 Company Overview
12.5.3 Financial Analysis
12.5.3.1 Net Revenue, 2017-2021
12.5.4 Product Benchmarking
12.5.5 Strategic Outlook
12.6 Bluebird Bio, Inc.
12.6.1 Company Snapshot
12.6.2 Company Overview
12.6.3 Financial Analysis
12.6.3.1 Net Revenue, 2017-2021
12.6.3.2 R&D, 2017-2021
12.6.4 Product Benchmarking
12.6.5 Strategic Outlook
12.7 Bristol Myers Squibb
12.7.1 Company Snapshot
12.7.2 Company Overview
12.7.3 Financial Analysis
12.7.3.1 Net Revenue, 2017-2022
12.7.3.2 R&D, 2017-2022
12.7.3.3 Regional Market Shares, 2022
12.7.4 Product Benchmarking
12.7.5 Strategic Outlook
12.8 Gilead Sciences, Inc.
12.8.1 Company Snapshot
12.8.2 Company Overview
12.8.3 Financial Analysis
12.8.3.1 Net Revenue, 2017-2022
12.8.3.2 R&D, 2017-2021
12.8.3.3 Regional Market Shares, 2022
12.8.4 Product Benchmarking
12.8.5 Strategic Outlook
12.9 Integra LifeSciences
12.9.1 Company Snapshot
12.9.2 Company Overview
12.9.3 Financial Analysis
12.9.3.1 Net Revenue, 2017-2021
12.9.3.2 R&D, 2017-2021
12.9.3.3 Regional Market Shares, 2021
12.9.4 Product Benchmarking
12.9.5 Strategic Outlook
12.10 Mesoblast Ltd
12.10.1 Company Snapshot
12.10.2 Company Overview
12.10.3 Financial Analysis
12.10.3.1 Net Revenue, 2017-2022
12.10.3.2 R&D, 2017-2021
12.10.4 Product Benchmarking
12.10.5 Strategic Outlook
12.11 Novartis AG
12.11.1 Company Snapshot
12.11.2 Company Overview
12.11.3 Financial Analysis
12.11.3.1 Net Revenue, 2017-2022
12.11.3.2 R&D, 2017-2022
12.11.3.3 Regional Market Shares, 2022
12.11.4 Product Benchmarking
12.11.5 Strategic Outlook
12.12 Organogenesis Inc.
12.12.1 Company Snapshot
12.12.2 Company Overview
12.12.3 Financial Analysis
12.12.3.1 Net Revenue, 2017-2021
12.12.3.2 R&D, 2017-2021
12.12.4 Product Benchmarking
12.12.5 Strategic Outlook
12.13 Sarepta Therapeutics, Inc.
12.13.1 Company Snapshot
12.13.2 Company Overview
12.13.3 Financial Analysis
12.13.3.1 Net Revenue, 2017-2021
12.13.3.2 R&D, 2017-2021
12.13.4 Product Benchmarking
12.13.5 Strategic Outlook
12.14 Sibiono GeneTech Co. Ltd
12.14.1 Company Snapshot
12.14.2 Company Overview
12.14.3 Product Benchmarking
12.15 Smith & Nephew plc
12.15.1 Company Snapshot
12.15.2 Company Overview
12.15.3 Financial Analysis
12.15.3.1 Net Revenue, 2017-2021
12.15.3.2 R&D, 2017-2021
12.15.3.3 Regional Market Shares, 2021
12.15.4 Product Benchmarking
12.15.5 Strategic Outlook
12.16 Terumo BCT
12.16.1 Company Snapshot
12.16.2 Company Overview
12.16.3 Financial Analysis
12.16.3.1 Net Revenue, 2017-2021
12.16.3.2 R&D, 2017-2021
12.16.3.3 Regional Market Shares, 2021
12.16.4 Product Benchmarking
12.16.5 Strategic Outlook

13 Conclusion and Recommendations
13.1 Concluding Remarks from
13.2 Recommendations for Market Players



★調査レポート[世界の再生医療市場（2023-2033)：製品別（細胞治療（自己由来、同種由来）、組織エンジニアリング（足場材、ヒドロゲル）、遺伝子治療、その他）、用途別（腫瘍、皮膚科、筋骨格、神経内科、循環器科、創傷治療、眼科、その他）、地域別] (コード：VGA23MA027)販売に関する免責事項を必ずご確認ください。
★調査レポート[世界の再生医療市場（2023-2033)：製品別（細胞治療（自己由来、同種由来）、組織エンジニアリング（足場材、ヒドロゲル）、遺伝子治療、その他）、用途別（腫瘍、皮膚科、筋骨格、神経内科、循環器科、創傷治療、眼科、その他）、地域別]についてメールでお問い合わせ
◆関連市場調査レポート◆
  • 世界の再生医療市場（～2028年）：製品別（幹細胞（自己由来、同種異系）、免疫療法、遺伝子療法、ティッシュエンジニアリング）、用途別（筋骨格系、がん、皮膚科、創傷治療、心血管疾患、眼疾患）
  • 世界のバイオプリザベーション市場（2023-2033)：製品別（機器（冷凍庫、冷蔵庫、消耗品、液体窒素）、培地（調剤型、自家調製型）、検査情報管理システム（LIMS））、用途別（再生医療（細胞治療、遺伝子治療）、バイオバング（ヒト卵子、ヒト精子）、創薬）、細胞プロバイダー別（CD34+、CD19+、その他）、地域別
  • 世界の多血小板血漿療法 (PRP)市場（～2030年）：種類別（純血小板豊富血漿（P-PRP）、白血球豊富血小板豊富血漿（L-PRP）、純血小板豊富フィブリン（P-PRF）、白血球豊富血小板豊富フィブリン（L-PRF）、活性化PRP、自己調整血漿（ACP）、細胞PRP、その他）、供給源別（自己由来、同種由来、その他）、用途別、エンドユーザー別、地域別
  • 世界の臨床試験用画像市場（2023-2033)：ソフトウェア・サービス別（ソフトウェア、サービス）、モダリティ別（コンピューター断層撮影、磁気共鳴画像診断、超音波診断、その他）、治療領域別（腫瘍、感染症、神経内科、CVS）、エンドユーザー別（製薬企業、バイオテクノロジー企業、医療機器メーカー、その他）、地域別
  • 世界の再生医療市場（～2027）：製品別（前駆細胞、幹細胞療法、遺伝子治療、その他）、材料別（遺伝子操作材料、合成材料、その他）、用途別（腫瘍、創傷ケア、その他）、エンドユーザー別、地域別
  • 世界の先進治療薬CDMO市場2023-2030：製品別（遺伝子治療、細胞治療、組織工学）、フェーズ別、疾患別、地域別
  • 世界の先進治療薬（ATMP）市場2023-2030：治療タイプ別（細胞治療、遺伝子治療、組織工学製品）、地域別（北米、ヨーロッパ、アジア太平洋、その他地域）
  • 世界の細胞株開発市場2023-2033：種類別（免疫療法細胞株、イオンチャネル細胞株、GPCR細胞株、細胞シグナル伝達経路用細胞株、遺伝子ノックアウト細胞株、がん細胞株）、用途別（創薬・開発、基礎研究、毒性スクリーニング、バイオ医薬品生産、薬物スクリーニング、組織エンジニアリング、法医学検査）、エンドユーザー別（バイオ医薬品企業、受託研究機関（CRO）、学術・研究機関、法医学研究所、食品・飲料企業、診断センター）、地域別

    • ◆H&Iグローバルリサーチのお客様（例）◆